ISG wins £50m deal for reconfigurable cancer centre
ISG has won a £50m contract to build a cancer centre for the Royal Marsden in London.
The facility will feature large open floor plates and reconfigurable spaces so that accommodation can be adapted as new treatments evolve.
The Oak Cancer Centre will sit at the gateway to the Royal Marsden’s Sutton site. It will provide outpatient facilities, medical day-care and collaboration space for clinical researchers to accelerate cancer diagnosis and treatment for patients.
It has been named after the Oak Foundation, which has donated £25m to the cost of the facility.
The new six-storey, 134,000 sq ft concrete frame building is targeting a BREEAM Excellent environmental performance rating and will become the centrepiece of an ambitious plan, alongside academic partner, The Institute of Cancer Research, to create a £1bn cancer research campus – The London Cancer Hub, in Sutton.
Floor layouts and high specification materials have been elected with the patient experience at the heart of the process. At ground floor level a large full height atrium will flood the reception with natural light. A saw-tooth roof design allows light to enter the building, whilst providing space for a large photovoltaic array to generate electricity.
Constructed on a sloping brownfield site, patient areas extend across the lower ground floor through to level two, with the two upper floors providing space for The Royal Marsden’s team of cancer researchers. Facilities include a Rapid Diagnostic Centre and a new Medical Day Unit for patients to receive chemotherapy treatment.
The building will feature extensive curtain walling and brise soleil solar shading elements to its façade, with the project scheduled for completion in summer 2022.
Lee Hutchinson, managing director for ISG’s science and health business, said: “Creating leading-edge healthcare facilities that enable clinicians and researchers to improve patient outcomes is a direct way that the construction industry can make a positive societal impact with a multi-generational legacy.
“The unprecedented nature of this current global health crisis has acutely focused attention on a sector that we all rely upon, and one so intrinsically linked to the physical infrastructure that supports patient outcomes and the research and development that is transformative to our lives. This is a project of major significance for our business, with every member of the delivery team fully focused on creating a world-leading hub for treatment and research into cures for cancer.”